MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor
02 Junho 2023 - 9:00AM
Business Wire
MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”), a
clinical-stage pharmaceutical company focused on advancing new
therapies for cancer, today announced that, in connection with the
Company’s previously announced succession plan, Daniel P. Gold,
Ph.D’s tenure as the president and chief executive officer of MEI
will end on June 2, 2023 and the Company’s board of directors has
appointed David M. Urso as his successor. Mr. Urso, who joined the
Company in 2014 and has been serving as the company’s chief
operating officer since 2018, will also join the board of
directors. Dr. Gold will remain on MEI’s board, where he will
continue to share his extensive knowledge and experience with the
company.
“I am very proud of the team we have built since I joined MEI as
CEO in 2010. Together, we have progressed the company’s development
portfolio by identifying exciting, novel oncology candidates and
advancing them through clinical development,” said Dr. Gold. “As
the company enters its next stage of growth, it’s the right time
for David to take the reins as MEI’s next president and CEO. David
joined MEI in 2014, and since that time, he has exhibited
tremendous leadership across the organization. Importantly, he has
been my partner in developing and overseeing the implementation of
corporate strategy, while leading our business development
efforts.”
Charles V. Baltic III, J.D., chair of the board of MEI added,
“Succession planning is a significant focus of the MEI Board and we
are pleased to have worked closely with Dan and David over the past
few months to ensure a smooth transition. Dan has done an
incredible job in building MEI’s capabilities and in-licensing
promising, novel cancer drug candidates, all while forming and
fostering a strong culture for the organization and its employees.
On behalf of the board, I would like to thank Dan for his
outstanding leadership and his tireless commitment to the company
and patients in the advancement of treatments for cancer. We wish
him all the best in his retirement and look forward to continuing
to leverage his knowledge, insights, experience and commitment as
he maintains his role on the MEI board.”
Mr. Urso commented, “Dan’s exceptional leadership and commitment
has set the tone as MEI’s top executive for over 10 years. I’ve
always admired his scientific acumen, strategic thinking and his
ability to build a strong and passionate team. I’m looking forward
to continuing MEI’s mission – including through the advancement of
our two exciting clinical-stage programs, voruciclib and ME-344
that were identified under Dan’s leadership – while also continuing
to inspire the best efforts from my colleagues.”
Mr. Urso joined MEI Pharma in April 2014 with nearly two decades
of experience in the life science industry as a senior vice
president and general counsel. In July 2018, he was appointed MEI’s
chief operating officer. Previously, he was chief operating officer
and general counsel at Tioga Pharmaceuticals, a privately held drug
development company he co-founded in 2005 as a principal at Forward
Ventures, where he was responsible for identifying and developing
life science venture capital investments. Before joining Forward
Ventures in 2002, David was director of corporate development and
legal affairs at DNA Sciences. Previously, he worked as an attorney
in the corporate securities and licensing groups at Wilson Sonsini
Goodrich & Rosati LLP and Cooley Godward LLP, after beginning
his career as a bench scientist at SmithKline Beecham and the
University of Pennsylvania Medical School. Mr. Urso received a J.D.
from Harvard Law School and a bachelor's degree in Molecular
Biology and Philosophy from Reed College.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company
focused on developing potential new therapies for cancer. MEI
Pharma’s portfolio of drug candidates includes clinical stage
candidates with differentiated mechanisms of action intended to
address unmet medical needs and deliver improved benefit to
patients, either as standalone treatments or in combination with
other therapeutic options. For more information, please visit
www.meipharma.com. Follow us on Twitter @MEI_Pharma and on
LinkedIn.
Forward-Looking Statements
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical studies and approved by the FDA as being
safe and effective for the intended use. Statements included in
this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995 including, without limitation, statements regarding: the
potential, safety, efficacy, and regulatory and clinical progress
of zandelisib and our other product candidates, including the
anticipated timing for initiation of clinical trials and release of
clinical trial data and our expectations surrounding potential
regulatory submissions, approvals and timing thereof, our business
strategy and plans; and the sufficiency of our cash, cash
equivalents and short-term investments to fund our operations. You
should be aware that our actual results could differ materially
from those contained in the forward-looking statements, which are
based on management's current expectations and are subject to a
number of risks and uncertainties, including, but not limited to
our failure to successfully commercialize our product candidates;
the availability or appropriateness of utilizing the FDA’s
accelerated approval pathway for our product candidates; final data
from our pre-clinical studies and completed clinical trials may
differ materially from reported interim data from ongoing studies
and trials; costs and delays in the development and/ or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in
clinical trial results; adverse effects on the Company's business
as a result of the restatement of our previously issued financial
statements; uncertainty regarding the impact of rising inflation
and the increase in interest rates as a result; the impact of the
COVID-19 pandemic on our industry and individual companies,
including on our counterparties, the supply chain, the execution of
our clinical development programs, our access to financing and the
allocation of government resources; our inability to maintain or
enter into, and the risks resulting from our dependence upon,
collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and
distribution of any products; competitive factors; our inability to
protect our patents or proprietary rights and obtain necessary
rights to third party patents and intellectual property to operate
our business; our inability to operate our business without
infringing the patents and proprietary rights of others; general
economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required
financing; technological changes; government regulation; changes in
industry practice; and one-time events. We do not intend to update
any of these factors or to publicly announce the results of any
revisions to these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230602005060/en/
David A. Walsey Tel: 858-369-7104 investor@meipharma.com
Joele Frank, Wilkinson Brimmer Katcher Dan Katcher / Aaron
Palash Tel: 212-355-4449 MEIP-jf@joelefrank.com
MEI Pharma (NASDAQ:MEIP)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
MEI Pharma (NASDAQ:MEIP)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024